Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Increases By 5.1%

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 164,300 shares, an increase of 5.1% from the May 31st total of 156,400 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 405,600 shares, the short-interest ratio is currently 0.4 days.

IceCure Medical Stock Down 0.2 %

Shares of NASDAQ:ICCM traded down $0.00 during trading hours on Wednesday, reaching $0.74. The stock had a trading volume of 50,869 shares, compared to its average volume of 488,316. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $1.57. The firm’s 50 day moving average is $0.97 and its 200-day moving average is $1.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.88 and a current ratio of 3.39. The stock has a market capitalization of $33.76 million, a price-to-earnings ratio of -2.25 and a beta of 0.57.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.80 million. IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. During the same period last year, the firm posted ($0.08) EPS. Research analysts predict that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ICCM shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of IceCure Medical in a research note on Tuesday. Alliance Global Partners increased their price objective on shares of IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research report on Wednesday, March 20th.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.